Phar­ma­cyclics bil­lion­aire Bob Dug­gan takes the helm of an­oth­er biotech — and he faces an even big­ger up­hill climb this time

Five years af­ter turn­ing his stake in Phar­ma­cyclics in­to a per­son­al for­tune worth more than a bil­lion dol­lars, Bob Dug­gan is back at the helm of a biotech. He’s once again fight­ing the odds in mak­ing a biotech a suc­cess — but this time in­stead of on­col­o­gy, where he made biotech his­to­ry with Im­bru­vi­ca, he’s tak­en the reins on a late-stage pro­gram for an an­tibi­ot­ic.

And noth­ing is quite as chilly right now as an­tibi­otics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER